Enhanced activity of linezolid against Staphylococcus aureus in cerebrospinal fluid

Res Microbiol. 2012 Apr;163(3):157-60. doi: 10.1016/j.resmic.2011.12.004. Epub 2011 Dec 16.

Abstract

Linezolid is considered for treatment of central nervous system (CNS) infections caused by multidrug-resistant Gram-positive bacteria. Therefore, the influence of cerebrospinal fluid (CSF) on the antimicrobial activity of linezolid was evaluated in vitro. Time-kill curves were conducted in CSF and Mueller-Hinton broth (MHB) using Staphylococcus aureus (ATCC 29213) and Staphylococcus epidermidis (ATCC 12228) strains. In CSF lower linezolid concentrations were needed against S. aureus (1× MIC) and S. epidermidis (0.5× MIC) to achieve bacteriostasis than in MHB (4× MIC for both strains). Good activity of linezolid in CSF supports performance of clinical trials evaluating its potential for treatment of CNS infections.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetamides / pharmacology*
  • Anti-Bacterial Agents / pharmacology*
  • Cerebrospinal Fluid / microbiology*
  • Humans
  • Linezolid
  • Microbial Sensitivity Tests
  • Microbial Viability / drug effects
  • Oxazolidinones / pharmacology*
  • Staphylococcus aureus / drug effects*
  • Staphylococcus epidermidis / drug effects

Substances

  • Acetamides
  • Anti-Bacterial Agents
  • Oxazolidinones
  • Linezolid